Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Aramchol Meglumine vs Aramchol Free Acid in Healthy Volunteers
NCT06502561Phase 1Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aramchol in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Galmed Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at 8 days, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 8 days and 1 more. Started Feb 2025; status: completed.
02
Drugs
aramchol
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06502561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502561.